Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials.
Bieber T, Thyssen JP, Reich K, Simpson EL, Katoh N, Torrelo A, De Bruin-Weller M, Thaci D, Bissonnette R, Gooderham M, Weisman J, Nunes F, Brinker D, Issa M, Holzwarth K, Gamalo M, Riedl E, Janes J. Bieber T, et al. Among authors: holzwarth k. J Eur Acad Dermatol Venereol. 2021 Feb;35(2):476-485. doi: 10.1111/jdv.16948. Epub 2020 Oct 6. J Eur Acad Dermatol Venereol. 2021. PMID: 32926462
Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5).
Simpson EL, Forman S, Silverberg JI, Zirwas M, Maverakis E, Han G, Guttman-Yassky E, Marnell D, Bissonnette R, Waibel J, Nunes FP, DeLozier AM, Angle R, Gamalo M, Holzwarth K, Goldblum O, Zhong J, Janes J, Papp K. Simpson EL, et al. Among authors: holzwarth k. J Am Acad Dermatol. 2021 Jul;85(1):62-70. doi: 10.1016/j.jaad.2021.02.028. Epub 2021 Feb 16. J Am Acad Dermatol. 2021. PMID: 33600915 Clinical Trial.
Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study.
King B, Ko J, Forman S, Ohyama M, Mesinkovska N, Yu G, McCollam J, Gamalo M, Janes J, Edson-Heredia E, Holzwarth K, Dutronc Y. King B, et al. Among authors: holzwarth k. J Am Acad Dermatol. 2021 Oct;85(4):847-853. doi: 10.1016/j.jaad.2021.05.050. Epub 2021 Jun 16. J Am Acad Dermatol. 2021. PMID: 34090959 Free article. Clinical Trial.
Two Phase 3 Trials of Baricitinib for Alopecia Areata.
King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, Hordinsky M, Dutronc Y, Wu WS, McCollam J, Chiasserini C, Yu G, Stanley S, Holzwarth K, DeLozier AM, Sinclair R; BRAVE-AA Investigators. King B, et al. Among authors: holzwarth k. N Engl J Med. 2022 May 5;386(18):1687-1699. doi: 10.1056/NEJMoa2110343. Epub 2022 Mar 26. N Engl J Med. 2022. PMID: 35334197 Clinical Trial.
Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials.
Bieber T, Katoh N, Simpson EL, de Bruin-Weller M, Thaçi D, Torrelo A, Sontag A, Grond S, Issa M, Lu X, Cardillo T, Holzwarth K, Thyssen JP. Bieber T, et al. Among authors: holzwarth k. J Dermatolog Treat. 2023 Dec;34(1):2161812. doi: 10.1080/09546634.2022.2161812. J Dermatolog Treat. 2023. PMID: 36546346 Free article.
13 results